High-throughput screening with a miniaturized radioligand competition assay identifies new modulators of human α2-adrenoceptors.
Human α(2)-adrenoceptors (α(2)-ARs) are rhodopsin-like G-protein coupled receptors, and potential drug targets. The three different human α(2)-AR subtypes α(2A), α(2B) and α(2C) are widely distributed in tissues, but so far only a few subtype-selective ligands have been identified. In this project, we set off to conduct a large chemical screen for activity on the human α(2B)-AR and studied the selectivity of the active compounds towards the human α(2A)- and α(2C)-AR subtypes. We employed a radioligand competition binding assay that was optimized and miniaturized into a robotic environment. Membrane fractions containing recombinant human receptor subtypes were prepared from stably transfected Chinese hamster ovary (CHO) cell lines. Initially identified hits were followed up and characterized, and chemoinformatics tools were applied to gain better understanding of the relevance of the results. After a primary screen against α(2B)-AR, 176 compounds of the 17,952 included in the library were declared as active at 10 μM, of which 89 compounds were further selected for potency and affinity determinations using the three human α(2)-AR subtypes. One of the identified positive hits was 2″,2″″-Bisepigallocatechin digallate, which was found to have high affinity at all three human α(2)-AR subtypes. This represents the first non-protonable molecule identified as able to interact with these receptors. Additionally, results obtained with a functional assay (agonist-induced stimulation of [(35)S]GTPγS binding) supported the identification of another positive hit, lysergol, as a partial agonist of the human α(2)-AR subtypes. The dataset of confirmed active chemical species represents a readily available, high quality source for follow-up studies. Altogether, these results provide novel research approaches for drug discovery of modulators of the α(2)-AR subtypes.